A pooled analysis using data from eight GBG trials (GeparDuo, GeparTrio pilot and main, GeparQuattro, AGO-1, PREPARE, TECHNO; GeparQuinto) that aimed to help selecting appropriately the elderly women who would benefit from neoadjuvant chemotherapy has been published in the Oncotarget.
Ageing process is the biggest risk factor for the development of breast cancer. In Germany a survey showed that more than half of all breast cancer patients are older than 65 years and more than a third are older than 70 years. Therefore, the management of older breast cancer patients is challenging. This pooled analysis demonstrated an unfavorable impact of ageing process on pathological complete response (pCR), especially for TNBC but it showed a realistic chance for pCR when neoadjuvant chemotherapy is applied, especially for HER2-positive elderly patients.
von Waldenfels G, Loibl S, Furlanetto J, Machleidt A, Lederer B, Denkert C, Hanusch C, Kümmel S, von Minckwitz G, Schneeweiss A, Untch M, Rhiem K, Fasching PA, Blohmer JU. Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Oncotarget. 2018;9:15168-15179.
Link in PubMed